Background-Catecholaminergic polymorphic ventricular tachycardia is an uncommon, potentially lethal, ion channelopathy.
C atecholaminergic polymorphic ventricular tachycardia (CPVT) is an uncommon cardiac ion channelopathy that causes sudden unexpected death (SUD) of the young. CPVT has been described as the most lethal of the ion channelopathies. [1] [2] [3] [4] [5] As many as 30% of patients experience SUD as an initial presentation, and up to half experience cardiac arrest by 20 to 30 years of age. [6] [7] [8] Pathological arrhythmias arise from inappropriate handling of calcium release in the cardiomyocyte. 9 These arrhythmias predispose affected individuals to syncope, seizure, cardiac arrest, and SUD. [5] [6] [7] [8] 10 A pathognomonic exercise stress test (EST) demonstrates increasing ventricular ectopy with progressive adrenergic drive, often culminating in bidirectional or polymorphic VT. 11, 12 Mutations in the ryanodine receptor-2 (RyR2) gene are implicated in approximately half of cases. 6, 9 armamentarium. [16] [17] [18] [19] [20] No controlled trials exist, although one is currently underway evaluating flecainide. Limited data suggest that verapamil and left cardiac sympathetic denervation (LCSD) may also be effective therapies. 8, 13, [21] [22] [23] [24] [25] Because of the high lethality of CPVT, implantable cardioverter defibrillators (ICDs) are recommended for those with refractory arrhythmias 12 ; however, their efficacy and safety have recently been challenged. 26, 27 Children with CPVT are usually more severely affected than adults 4 ; however, no large studies focusing on the pediatric population exist. Data on novel therapies in children, including flecainide and LCSD, are scarce. Although access to cascade genetic screening has provided diagnostic clarity, it also identifies young, asymptomatic children, and appropriate management and outcome in this population are unknown. Using a large cohort of pediatric patients with CPVT, we sought to investigate the clinical characteristics, therapeutic strategies, and long-term outcomes in children.
Methods
This is a retrospective, observational cohort study of CPVT patients from 27 pediatric centers. Participating centers were solicited through the Pediatric and Congenital Electrophysiology Society. Data sharing agreements and local ethics approval were obtained by each center.
Inclusion Criteria
Enrolment included (1) patients diagnosed with CPVT reporting a cardiac symptom onset before 19 years of age or (2) asymptomatic patients diagnosed with CPVT before 19 years of age. A diagnosis of CPVT must have been established based on exercise and genetic testing by the participating institution at the time of entry.
Data Collection
Data were obtained from existing medical records and entered by participating centers at each site on to a data collection form. Entries were verified by the coordinating center. Study data were collected and managed using REDCap 28 electronic data capture tools hosted by the Child and Family Research Institute at British Columbia Children's Hospital.
Definitions
Treatment failure was defined as syncope and cardiac arrest while on medication and each occurrence is reported as a treatment failure event. A pediatric formulary was used to assist in establishing target dosages of medications as outlined in Table 1 . 29 In patients with ICDs, electrical storm was defined as >3 discharges in a 24-hour period. Ventricular ectopy was defined as documented ventricular couplets, frequent premature ventricular complexes and bigeminy, and sustained or nonsustained VT. A recent cardiac arrest was defined as ≥1 cardiac arrest(s) in the 6 months preceding the date of last follow-up.
Statistical Analysis
Frequency tables were generated for all categorical data with the frequency (percentage) reported. A generalized linear model (PROC GENMOD, probability distribution=binomial; link=logit) was used to test the effect of selected parameters on correlated samples. χ 2 values were calculated to test for group differences of both independent and correlated samples. Continuous data were analyzed using a univariate procedure. Data are presented as the median (interquartile range). A Wilcoxon rank-sum test was used to test for group differences. All analyses were 2-sided with a P value <0.05 considered statistically significant. Dates of birth were collected as year and month only, as per ethical considerations. Durations listed therefore vary by ±1 month. All statistical analyses were completed using SAS Statistical Software Version 9.3 (SAS Institute, Cary, NC).
Results

Demographic Information and Diagnosis
Our cohort included 226 patients (51% women) with CPVT from 27 pediatric centers, including 170 (75%) probands and 56 (25%) relatives. Most patients were of white ethnicity 
WHAT THE STUDY ADDS
• The present study describes therapeutic outcomes in the largest reported population of patients with catecholaminergic polymorphic ventricular tachycardia.
• Treatment failure, suboptimal dosing, and nonadherence on β-blocker therapy were prevalent in this large cohort of pediatric patients.
• Flecainide was associated with a low risk of life-threatening cardiac events when used in combination with a β-blocker. Flecainide has been used as monotherapy in a limited number of patients.
• More than half of this cohort received an implantable cardioverter defibrillator despite concerns associated with implantable cardioverter defibrillator placement in patients with catecholaminergic polymorphic ventricular tachycardia. These patients experienced high rates of device-related complications, including electrical storm and inappropriate discharges.
(65%). Ethnicity was not associated with age of symptom onset in those presenting with cardiac symptoms. There were 176 patients (78%) who presented with symptoms and 43 (19%) who were asymptomatic, evaluated as part of family screening. In patients presenting with family history alone, SUD of a relative at <40 years of age was reported in 32 of 43 (74%). A total of 7 patients came to medical attention incidentally and did not have symptoms or family history of CPVT on presentation. Syncope was the most frequent symptomatic presentation in 112 patients (64%), followed by cardiac arrest in 58 (33%), palpitations in 13 (7%), and chest pain in 7 (4%). There was no sex predilection to presentation with cardiac arrest (53% men; P=0.34). Only 2 (1%) experienced SUD as an initial presentation. The median age of symptom onset was 10. 
Clinical Course
Symptoms of CPVT occurred in 176 of 226 patients (78%; 47% men), including syncope in 122 (54%) and cardiac arrest in 86 (38%; 51% men). Probands were more likely to experience syncope (65% versus 25%; P<0.001) and cardiac arrest (48% versus 9%; P<0.001) compared with their affected family members. In follow-up, cardiac arrest did not occur in any patients who had presented without symptoms. Circumstances preceding syncope and cardiac arrest are summarized in Fig 
Pharmacological Management
Pharmacological therapy was prescribed to 211 patients (93%). Treatment status was unknown in 3 (1%) and 10 (5%) never received any pharmacological therapy. Of the 10 patients never on therapy, 1 (10%) had a known or possible mutation in RyR2 but no symptoms or documented arrhythmia. However, 3 (30%) had ventricular ectopy and 4 (40%) had cardiac symptoms. Three (30%) deceased patients received an ICD before their death. Death occurred in 1 patient (10%) never on therapy. No adjustments in initial pharmacological therapy were made in half of the 211 patients on treatment.
β-Blockers
A β-blocker was used in 205 of 211 patients (97%) with known treatment status. The initial β-blockers used included nadolol in 90 (44%), atenolol in 60 (29%), metoprolol in 33 (16%), and propranolol in 15 (7%). A β-blocker was subsequently discontinued in 49 patients (24%). A different type of β-blocker was restarted at some point in 48 of these patients (98%). Types of β-blockers started subsequently included nadolol in 25 (52%), metoprolol in 7 (15%), atenolol in 6 (13%), propranolol in 4 (8%), and bisoprolol in 4 (8%). Symptoms despite previous therapy and intolerance to previous therapy were cited as rationale for starting a subsequent β-blocker in 25 patients (52%) and persistent ventricular ectopy in 16 (33%). Adverse effects were cited as rationale for discontinuation of initial therapy in 16 (33%), accounting for 8% of all patients on β-blockers. Patients were also frequently discontinued on a β-blocker because of increasing cardiac symptoms in 13 (27%) and persistent ventricular ectopy in 8 (16%). In 6 patients, β-blockers were discontinued altogether. Treatment failure events, defined as syncope and cardiac arrest while on a medication, occurred in 53 patients (25%). A total of 84 discrete treatment failure events occurred in 43 patients. In 10 patients, the exact number of treatment failure events was unknown. Of the 84 treatment failure events, 44 (52%) were syncope and 40 (48%) were cardiac arrest as summarized in Table 2 . Treatment failure occurred 82 times despite β-blocker therapy, and 48 events (59%) occurred on optimal doses as outlined in Table 3 . Nonoptimal dosing could be attributed to 33 events (40%) on β-blockers. Poor adherence contributed to 40 events (48%). An additional 10 patients (15%) had at least 1 treatment failure event on an unverified dose of a β-blocker. Probands were more likely to experience treatment failure than family members (23% versus 7%; P=0.008). The type of β-blocker and sex did not influence the likelihood of treatment failure. Only 5 patients (2%) on a β-blocker died.
Calcium Channel Blockers
A calcium channel blocker was used in 19 of 211 patients (9%), as initial therapy in 5 (2%) and as subsequent therapy in 14 (7%). Verapamil was used in 17 patients (89%). Persistent ventricular ectopy was cited in 12 patients (63%) as rationale for using a calcium channel blocker and persistent symptoms despite previous therapy in 6 (32%). Treatment failure events on the small number of patients receiving a calcium channel blocker are summarized in Tables 2 and 3 .
Flecainide
Flecainide was used in 51 of 211 patients (24%), initially in combination with a β-blocker in 6 (12%) and subsequently in 45 (88%). Rationale for adding flecainide to a β-blocker included ongoing ventricular ectopy in 34 patients (78%), symptoms despite previous therapy in 6 (13%), and a history of cardiac arrest in 4 (9%). β-blockers were continued after initiation of flecainide in 43 (96%). After flecainide was added to a β-blocker, 24 patients (53%) were asymptomatic and 17 (38%) had persistent ventricular ectopy. There were 8 treatment failure events in those receiving flecainide; however, 7 events (88%) occurred on a suboptimal dose and 6 events (88%) occurred in the context of nonadherence. Treatment failure never occurred in any adherent patient receiving optimal doses of both flecainide and a β-blocker. Flecainide was discontinued in 5 patients (10%) because of persistent or increasing side effects and ventricular ectopy in 4 (80%). Five patients received flecainide as monopharmacological therapy (Table 4) 
Interventional Management
Implantable Cardioverter Defibrillator
ICDs were implanted in 121 patients (54%), most often for history of cardiac arrest in 67 (55%), primary prophylaxis, including ventricular ectopy despite previous therapy in 27 (22%) and symptoms despite previous therapy in 17 (14%). One or more treatment failure events on a β-blocker were documented in 42 patients (35%). Appropriate shocks were experienced by 56 (46%) and inappropriate shocks occurred in 21 of 94 (22%) respondents. A history of multiple shocks was common, with 24 (43%) receiving ≥6 shocks. Seventeen (30%) received just 1 appropriate shock. Arrhythmia was terminated after appropriate shock in 31 patients (55%), but 9 (16%) had poor response to appropriate shocks, defined as failure to terminate the arrhythmia with >75% of discharges. Electrical storm occurred in 22 patients (18%). ICD-related complications occurred in 28 patients (23%), usually manifesting as lead problems in 16 (57%). There were no differences in number of appropriate shocks, success of shocks, or incidence of electrical storm between patients with and without history of cardiac arrest. Death occurred in 3 patients (2%) despite ICD placement, one of which was associated with electrical storm. This patient was receiving low-dose verapamil but optimally dosed atenolol (4 mg/kg per day). A second patient was receiving optimally dosed nadolol (1.5 mg/kg per day), whereas the third patient died at a peripheral center and treatment status could not be definitively determined. All 3 of these patients had cardiac arrest before ICD placement. Fifty-eight patients (48%) were asymptomatic after ICD placement; however, 30 (25%) had persistent ventricular ectopy, 13 (11%) experienced syncope, and 13 (11%) had subsequent cardiac arrest.
Left Cardiac Sympathetic Denervation
LCSD was performed in 18 patients (9 men), 9 had a history of cardiac arrest. The most common indication was novel conference/scientific data in 7 (39%). LCSD was used as primary therapy in 5 patients, because of a family history of severe phenotype in 1 and was undertaken in 4 patients without symptoms or ventricular ectopy. Eight patients (44%) underwent the procedure because of persistent symptoms and persistent, sustained VT. All patients were simultaneously on β-blockers and 3 patients were on flecainide. ICDs had been previously placed in 10 (56%). Complications related to LCSD were reported in 3 patients (16%), 2 with temporary Horner's syndrome and 1 with a hemothorax. After LCSD, 12 patients (67%) were asymptomatic. A reduction in ventricular ectopy was observed in this group with only 2 (11%) experiencing sustained VT during follow-up. Cardiac arrest was later reported in 1 patient, and syncope in another. See Table 5 for a description of patients with LCSD.
Deaths
Overall, there were 6 deaths (3%) in our cohort. One patient never received treatment and one was suspected to be nonadherent on a low dose of nadolol (0.36 mg/kg per day). Autopsy was performed in 1 case but the result was unknown. Two additional cases were ascertained postmortem after a pathological RyR2 mutation was found on molecular analysis. These patients are excluded from the total mortality calculation. One was found unresponsive on a rollercoaster and was later declared brain dead and the other experienced a cardiac arrest, had a catastrophic neurological injury, and was removed from life support. SUD was initially attributed to mitral valve prolapse in the latter patient; however, a brother was later diagnosed with phenotype and genotype positive CPVT. Subsequent testing of the deceased proband revealed the same RyR2 mutation. See Table 6 for a description of deceased patients.
Follow-Up
The cumulative length of follow-up was 3.5 (1.4-5.3) years, equivalent to 788 patient-years. One hundred sixty-eight of 226 patients (74%) were asymptomatic at last follow-up. Five patients (2%) reported a recent cardiac arrest, 4 (2%) reported syncope, and 15 (7%) had palpitations at last follow-up.
During follow-up, alterations to clinical management were made on the basis of an EST in 73 of 226 patients (32%). Increasing a medication dosage was the most frequent intervention in 54 (74%), followed by adding a new medication in 24 (33%), most commonly flecainide in 16 (67%). β-Blockers were stopped or decreased in 4 patients (5%) based on an EST result. An ICD was placed on the basis of an EST in 5 (7%) and an LCSD was performed in 1 (1%).
Discussion
This is a multicenter, retrospective observational cohort study including 226 pediatric patients followed up for a median of 3.5 years. To our knowledge, this study documents the largest cohort of patients with CPVT to date. Major findings include (1) higher rates of life-threatening symptoms and treatment failure events in probands; (2) no influence of sex on phenotype or treatment response; (3) substantial delay to diagnosis in many patients presenting symptomatically; (4) high rate of cardiac arrest and severe natural history of disease; (5) Near universal administration of β-blocker therapy; (6) high incidence of nonadherence, intolerance, subtherapeutic dosing, and treatment failure on β-blockers; (7) frequent use of ICDs, often implicated in life-threatening complications; (8) LCSD performed in a small number of patients; and (9) promising outcomes in patients receiving β-blocker-flecainide combination regimens.
A diagnosis of CPVT carries a high mortality rate. 1,2 Previous literature has largely failed to establish clear prognostic factors. Recent work by van der Werf et al 5 suggest that probands carrying RyR2 mutations are at higher risk of cardiac events. Our data expand on this observation and verify that both genotype-positive and genotype-negative probands have more severe manifestations of CPVT than their affected relatives. Sex did not correlate with age of symptom onset, risk of syncope, cardiac arrest, or treatment failure despite literature suggesting this trend. 14, 30, 31 These earlier findings may be attributable to smaller sample sizes. Delay to diagnosis in our cohort was substantial and concerning. A quarter of patients presenting symptomatically had a delay in diagnosis of >2.6 years despite initially reporting life-threatening cardiac events. CPVT is likely under-recognized, as many children were initially misdiagnosed with more common arrhythmic conditions. Clinicians often mistook arrhythmic syncope for benign or vasovagal syncope. This is despite the clinical history revealing adrenergic stress as a precipitant in more than three quarters of cases, a hallmark of several potentially lethal arrhythmic conditions. 32 Understandably, exercise restrictions and stress reduction are recommended in guidelines on CPVT. 12 Although a high rate of cardiac arrest was seen in our cohort, few patients experienced a recent cardiac arrest and most others were asymptomatic during follow-up, suggesting that regular contact with a cardiologist is important. Adjustments to medication and decisions to proceed to interventional strategies (ICD and LCSD) were frequently made on the basis of an abnormal EST during follow-up. This approach to therapeutic escalation has not been validated.
Death attributable to CPVT occurred in 6 patients, including several who were not on treatment. Unfortunately, SUD occurred in 2 asymptomatic patients, whereas others experienced cardiac arrest despite a previously normal phenotype. These concerning observations suggest that initiating and increasing treatment should not be made on the basis of symptoms alone. 4, 12, 15 Two patients were ascertained through molecular autopsy, a clinical scenario that may become more common as access to postmortem genetic sequencing improves. In 1 situation, a pediatric relative developed a phenotype and genotype consistent with CPVT, leading to positive postmortem genetic evaluation of his deceased sister. Unfortunately, the relative eventually passed away, suggesting a highly malignant phenotype in the family. β-Blocker failure was implicated in 3 deaths; 1 patient was previously asymptomatic on metoprolol and 2 had a history of refractory symptoms, highlighting the need for better tools to assess response to treatment. One patient had received an inappropriate diagnosis of arrhythmogenic right ventricular cardiomyopathy and was intermittently managed with β-blockers and amiodarone. Although a cardiac biopsy was reported to be mildly abnormal, an international expert felt that her history was consistent with CPVT. The marked heterogeneity of symptoms, response to treatment, and circumstances surrounding deaths in our cohort demonstrate the difficulty in predicting phenotype.
For ≈2 decades, the management of CPVT was limited to the use of β-blockers and ICDs. 6, 7, 13, 31 Evidence of treatment failure has mounted in recent years, including high rates of mortality on β-blockers. 4, 10, 13 Treatment failure events occurred in 1 in 4 patients on β-blockers and many reported adverse effects and nonadherence, reflecting observations from smaller series. 4, 10, 13 Recently, literature has suggested that nadolol, a longer acting β-blocker may be more protective in CPVT. 4 We did not observe this phenomenon in our cohort, although our study design was not powered to detect potential differences. Two patients received a diagnosis of CPVT during infancy based on a positive genetic test and family history; however, only 1 was treated with a β-blocker. No data currently exist to guide decisions in these situations. Although treatment failure is not uncommon, ≈1 in 5 untreated patients in our cohort died, supporting guidelines recommending β-blockers in all. 12 ICDs were implanted in more than half of patients for a variety of indications. Although most had a history of cardiac arrest, an ICD was placed for primary prophylaxis in one third of patients, usually in the context of ventricular ectopy. Guidelines do suggest ICD implantation in patients with cardiac arrest, recurrent syncope, and persistent ventricular ectopy. 12 However, our data, coupled with previous data by Miyake et al 26 show a high risk of complications, including electrical storm, lead wire fracture, and death in those with ICDs. Our data also suggest that many appropriate shocks do not terminate arrhythmias in CPVT. Children with CPVT may have particularly poor outcomes as frightening, painful shocks can precipitate electrical storm. 25 Family history of SUD may also motivate ICD placement, despite the variability of disease penetrance. 6, 9 ICDs may instead offer a false sense of security, and the risks and benefits of potentially lifelong implantation need to be carefully considered in each patient. To date, there are no controlled trials on ICDs in CPVT. Novel therapies, including flecainide and LCSD, may decrease ICD use in the future.
New therapeutic strategies, including flecainide and LCSD, were regularly attempted in our cohort. Flecainide showed positive results with just 7 treatment failure events reported in 50 patients receiving flecainide-β-blocker combination regimens. None occurred in adherent patients who were optimally dosed on both agents. This approach may be promising in probands, considering the significant risk of cardiac arrest in this population. Flecainide was also frequently implemented because of persistent ventricular ectopy and, in follow-up, approximately half of patients had arrhythmia suppression. Similar results were documented by van der Werf et al 18 in the original series assessing flecainide. Before this study, flecainide has only been reported in ≈5 patients <12 years of age. [16] [17] [18] 33 The pediatric data in our study are encouraging and suggest that flecainide should be considered in all patients with inadequate response to β-blockers. To our knowledge, we are the first to document favorable outcomes in a small number of patients treated with flecainide as monopharmacological therapy, characterized by prevention of cardiac arrest, syncope and seizure in all patients, and suppression of ventricular ectopy in half of patients. A larger study is needed to assess the role of flecainide as monopharmacological therapy.
Outcomes after LCSD seemed to be favorable with only 2 of 18 patients experiencing postprocedure treatment failure. Approximately half of the patients with an LCSD had suppression of arrhythmia in follow-up. Our results also describe 5 patients who underwent LCSD for primary prophylaxis, all of whom were asymptomatic subsequent to the procedure. LCSD also seems to be safe, with just 1 patient experiencing a serious, but nonfatal complication. Currently, guidelines list LCSD as a class IIb recommendation, stating that it may be attempted in patients with a refractory phenotype or β-blocker intolerance. 12 A small number of highly symptomatic patients responded well to LCSD. However, the procedure was mainly performed in patients with less malignant phenotypes, making it challenging to determine whether these results are meaningful. Further data on LCSD as an early intervention in CPVT are warranted. Despite several small studies on calcium channel blockers in CPVT, few patients in our cohort received verapamil. 8, 13, [21] [22] [23] [24] [25] Indications and outcomes for calcium channel blockers were variable and it is also difficult to draw conclusions from this small group.
Limitations
Our research was limited by selection bias, as those patients presenting with SUD are rarely diagnosed or seen by a cardiologist, and minimally symptomatic patients were less likely to meet inclusion criteria. A diagnosis of CPVT was required for enrolment; however, we were unable to determine strength of diagnosis in all cases and genetic reports were interpreted based on the information available for each mutation at the time of testing. Several centers did not have complete data on medication dosing, and no single published pediatric drug formulary provided target dosing for all therapies reported. We attempted to contact and verify clinical information with centers whenever possible.
Conclusions
CPVT is frequently characterized by a highly malignant phenotype, substantial delay to diagnosis and poor response to standard treatments. Probands are more severely affected than relatives with CPVT. In contrast to previous studies, sex does not seem to influence phenotype. Administration of β-blockers seems to be nearly universal. However, β-blocker therapy is complicated by nonadherence, intolerance, subtherapeutic dosing, and treatment failure. Although a newer option, flecainide was frequently prescribed and showed promising results. The substantial risk of cardiac arrest in CPVT may explain the high prevalence of ICDs. However, indication was variable, and complications, including life-threatening electrical storm, were not uncommon. Further data are needed to determine the role of LCSD in CPVT.
